Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00133874
Status:
COMPLETED
Last Update Posted:
2017-01-23
First Post:
2005-08-22
Brief Title:
Topical SB-275833 Ointment 1 For The Treatment Of Impetigo
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
An Observer-blind Multicenter Non-inferiority Comparative Study of the Safety and Efficacy of Topical 1 SB-275833 Ointment Applied Twice Daily for 5 Days Versus Topical 2 Fusidic Acid Cream Applied Three Times Daily for 7 Days in the Treatment Adult and Paediatric Subjects With Impetigo
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this study is to determine if topical SB-275833 ointment 1 is as safe and effective as topical sodium fusidate ointment 2 for the treatment of impetigo in adults and children as young as 9 months of age
Detailed Description:
A Randomised Observer-blind Multicentre Non-inferiority Comparative Phase III Study of the Safety and Efficacy of Topical 1 SB-275833 Ointment Applied Twice Daily for 5 Days versus Topical 2 Sodium Fusidate Ointment Applied Three Times Daily for 7 Days in the Treatment of Adult and Paediatric Subjects with Impetigo
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None